Tuoxin Pharmaceutical Group Co., Ltd. Class A

Tuoxin Pharmaceutical Group Co., Ltd. Class A

SSZSE:301089
19.73
CNY
-0.42
(-2.08%)
-0.63EPS
3.10BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 3.10B, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.10B
Enterprise Value2.91B

Share Statistics

As of September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A has 126.54M shares outstanding.

Shares Outstanding126.54M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 7.29, and the price-to-book ratio stands at 2.15.

PS Ratio7.29
PB Ratio2.15
P/TBV Ratio2.30

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 6.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.91B versus a market cap of 3.10B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.78

Financial Position

As of September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 3.93, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.15, indicating conservative leverage, while an interest coverage ratio of -642.70 demonstrates limited ability to service its debt obligations.

Current Ratio3.93
Quick Ratio1.38
Debt / Equity0.15
Debt / EBITDA-0.03
Interest Coverage-642.70

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 278,404.41 in revenue per employee across its workforce of 1,543.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee278,404.41
Employee Count1,543.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A recorded 1.18M in income tax expense. The company reported a pretax loss of -79.28M and -80.46M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax1.18M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 41.10% over the past 52 weeks. The 50-day moving average sits at 22.31, while the 200-day moving average is 25.03.

52-Week Price Change-41.10%
50-Day Moving Average22.31
200-Day Moving Average25.03

Income Statement

CNY

Over the twelve months ended September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A generated 429.58M in revenue and converted that into -80.46M in net income, yielding earnings per share of -0.63. EBITDA reached -78.80M, while operating income came in at -53.21M.

Revenue429.58M
Gross Profit81.47M
Operating Income-53.21M
Pretax Income-79.28M
Net Income-80.46M
EBITDA-78.80M
EBIT-78.80M
Earnings Per Share (EPS)-0.63

Balance Sheet

CNY

As of September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A holds 191.87M in cash and equivalents against 2.22M in total debt, resulting in a net debt position of -81.65M. Total book value stands at 1.45B, with working capital of 405.77M providing operational flexibility.

Cash & Cash Equivalents191.87M
Total Debt2.22M
Net Debt-81.65M
Equity (Book Value)1.45B
Book Value Per Share11.42
Working Capital405.77M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-55.41M

Margins

Over the twelve months ended September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 18.96, reflecting its pricing power and cost economics. The operating margin of -12.39 and net profit margin of -18.73 provide insight into operational efficiency.

Gross Margin18.96
Operating Margin-12.39
Pretax Margin-18.45
Profit Margin-18.73
EBITDA Margin-18.34

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Total shareholder yield reaches 0.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tuoxin Pharmaceutical Group Co., Ltd. Class A shareholders.

Shareholder Yield0.04

Scores

As of September 30, 2026, Tuoxin Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 11.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.98